Last reviewed · How we verify
NCT03963024: TrRaMM-TMI
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
Phase 1 trial testing Conditioning treatment "Treosulfan-TMI" in Irradiated Bone Marrow in 9 participants. Terminated before completion.
31 January 2019
Quick facts
| Lead sponsor | IRCCS San Raffaele |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 12 February 2014 |
| Primary completion | 31 January 2019 |
| Estimated completion | 31 January 2019 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Conditioning treatment "Treosulfan-TMI" — full drug profile →
- SCT
- GvHD prophylaxis — full drug profile →
Conditions studied
- Irradiated Bone Marrow — all drugs for Irradiated Bone Marrow →
- Transplant-Related Hematologic Malignancy — all drugs for Transplant-Related Hematologic Malignancy →
- Leukemia, Acute — all drugs for Leukemia, Acute →
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
IRCCS San Raffaele — full company profile →
Who can join
Adults 18 to 70, any sex, with Irradiated Bone Marrow or Transplant-Related Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
TrRaMM-TMI is a phase I trial to evaluate the feasibility and efficacy of an original sequential TMI/TrRaMM (Total Marrow Irradiation/Treosulfan-Rapamycin-Mycophenolate Mofetil) schedule in patients with hematological malignancies in advanced stage of disease undergoing an allogenic Stem Cell Transplant (SCT). The aim is to determine the maximum tolerated dose of TMI when combined with conditioning chemotherapy to transplant according to TrRaMM schedule.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.
Feng Y, Chen X, Cassady K, Zou Z, et al · · 2020 · cited 38× · PMID 33489922 · DOI 10.3389/fonc.2020.611690
Verify or expand the search:
- PubMed search for NCT03963024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other IRCCS San Raffaele trials
Trials by the same sponsor.
- NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
- NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
- NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
- NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
- NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03963024 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
- Last refreshed: 19 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03963024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing